Frequent amplifications and deletions of G1/S-phase transition genes, CCND1 and MYC in early breast cancers: A potential role in G1/S escape

Cancer Biomarkers

Volumn 5, Issue 1, 2009, Pages 41-49

  Jensen, L B ^a,b,c   Bartlett, J M S ^a   Witton, C J ^b,d   Kirkegaard, T ^a,b,e   Brown, S ^f   Muller S ^b   Campbell, F ^a   Cooke, T G ^c   Nielsen, Kirsten V ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b AGILENT TECHNOLOGIES   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d LiPlasome Pharma A/S   (Denmark)

^e DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^f GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Amplification; Breast cancer; CCND1; CCND3; CCNE1; CDK2; CDK6; Deletion; Fluorescence in situ hybridization; MYC

Indexed keywords

CCND3; CCNE1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 6; MYC PROTEIN; PROTEIN CCND1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE CONTROL; GENE DELETION; GENE MUTATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; TREND STUDY; VALIDATION PROCESS;

BREAST NEOPLASMS; CYCLIN D1; FEMALE; G1 PHASE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; S PHASE; SEQUENCE DELETION; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 61449122221     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2009-0570     Document Type: Article

References (31)

1. M.B. Kastan and J. Bartek, Cell-cycle checkpoints and cancer, Nature 432 (2004), 316-323.
2. K.I. Nakayama and K. Nakayama, Ubiquitin ligases: Cellcycle control and cancer, Nature Reviews Cancer 6 (2006), 369-381.
3. J. Massague, G1 cell-cycle control and cancer, Nature 432 (2004), 298-306.
4. A. Deshpande, P. Sicinski and P.W. Hinds, Cyclins and cdks in development and cancer: A perspective, Oncogene 24 (2005), 2909-2915.
5. C.J. Sherr and J.M. Roberts, Living with or without cyclins and cyclin-dependent kinases, Genes & Development 18 (2004), 2699-2711.
6. J. Sridhar, N. Akula and N. Pattabiraman, Selectivity and potency of cyclin-dependent kinase inhibitors, Aaps Journal 8 (2006), E204-E221.
7. C.E. Caldon, R.J. Daly, R.L. Sutherland and E.A. Musgrove, Cell cycle control in breast cancer cells, Journal of Cellular Biochemistry 97 (2006), 261-274.
8. A. Husdal, G. Bukholm and I.R.K. Bukholm, The prognostic value and overexpression of cyclin A is correlated with gene amplification of both cyclin A and cyclin E in breast cancer patient, Cellular Oncology 28 (2006), 107-116.
9. K. Kitahara, W. Yasui, H. Kuniyasu, H. Yokozaki, Y. Akama, S. Yunotani, T. Hisatsugu and E. Tahara, Concurrent amplification of cyclin cyclin E and CDK2 genes in colorectal carcinomas, International Journal of Cancer 62 (1995), 25-28.
10. M. Marone, G. Scambia, C. Giannitelli, G. Ferrandina, V. Masciullo, P. Benedetti-Panici and S. Mancuso, Analysis of cyclin E and CDK2 in ovarian cancer: Gene amplification and RNA overexpression, International Journal of Cancer 75 (1998), 34-39.
11. G. Callagy, P. Pharoah, S.F. Chin, T. Sangan, Y. Daigo, L. Jackson and C. Caldas, Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays, Journal of Pathology 205 (2005), 388-396.
12. J. Bondi, A. Husdal, G. Bukholm, J. M. Nesland, A. Bakka and I.R.K. Bukholm, Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome, Journal of Clinical Pathology 58 (2005), 509-514.
13. P. Schraml, C. Bucher, H. Bissig, A. Nocito, P. Haas, K. Wilber, S. Seelig, J. Kononen, M.J. Mihatsch, S. Dirnhofer and G. Sauter, Cyclin E overexpression and amplification in human tumours, Journal of Pathology 200 (2003), 375-382.
14. J. Palacios, E. Honrado, A. Osorio, A. Cazorla, D. Sarrio, A. Barroso, S. Rodriguez, J.C. Cigudosa, O. Diez, C. Alonso, E. Lerma, J. Dopazo, C. Rivas and J. Benitez, Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers, Breast Cancer Research and Treatment 90 (2005), 5-14.
15. B.J. Trask, Fluorescence in situ hybridization - applications in cytogenetics and gene-mapping, Trends in Genetics 7 (1991), 149-154.
16. D.J. Liao and R.B. Dickson, c-Myc in breast cancer, Endocrine-Related Cancer 7 (2000), 143-164.
17. M.B.K. Lambros, R. Natrajan and J.S. Reis-Filho, Chromogenic and fluorescent in situ hybridization in breast cancer, Human Pathology 38 (2007), 1105-1122.
18. T. Kirkegaard, K.V. Nielsen, L.B. Jensen, F.M. Campbell, S. Muller, S.M. Tovey, S. Brown, T.G. Cooke and J.M.S. Bartlett, Genetic alterations of CCND1 and EMSY in breast cancers, Histopathology 52 (2008), 698-705.
19. M. Vita and M. Henriksson, The Myc oncoprotein as a therapeutic target for human cancer, Seminars in Cancer Biology 16 (2006), 318-330.
20. S. Tovey, B. Dunne, C.J. Witton, A. Forsyth, T.G. Cooke and J.M.S. Bartlett, Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?, Clinical Cancer Research 11 (2005), 4835-4842.
21. X.W. She, J.E. Horvath, Z.S. Jiang, G. Liu, T.S. Furey, L. Christ, R. Clark, T. Graves, C.L. Gulden, C. Alkan, J.A. Bailey, C. Sahinalp, M. Rocchi, D. Haussler, R.K. Wilson, W. Miller, S. Schwartz and E.E. Eichler, The structure and evolution of centromeric transition regions within the human genome, Nature 430 (2004), 857-864.
22. K.V. Nielsen, S. Müller, T.S. Poulsen, S. Gabs and A. Schoenau, Combined Use of PNA and DNA for Fluorescence In Situ Hybridization (FISH), in: Peptide Nucleic Acids: Protocols and Applications, (2nd ed.), P.E. Nielsen, ed., Horizon Scientific Press, Framingham ME, Norwich, 2004.
23. R.A. Fisher, On the interpretation of X2 from contingency tables, and the calculation of P, 85 (1922), 87-94.
24. K. Vang Nielsen, B. Ejlertsen, S. Moller, J. Trost Jorgensen, A. Knoop, H. Knudsen and H.T. Mouridsen, The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D, Acta Oncol 47(4) (2008), 725-734.
25. A.S. Knoop, H. Knudsen, E. Balslev, B.B. Rasmussen, J. Overgaard, K.V. Nielsen, A. Schonau, K. Gunnarsdottir, K.E. Olsen, H. Mouridsen and B. Ejlertsen, Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group, Journal of Clinical Oncology 23 (2005), 7483-7490.
26. K. Park, S. Han, G.H. Gwak, H.J. Kim, J. Kim and K.M. Kim, Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer, Breast Cancer Research and Treatment 98 (2006), 337-342.
27. M. Varella-Garcia, Molecular cytogenetics in solid tumors: Laboratorial tool for diagnosis, prognosis, and therapy, Oncologist 8 (2003), 45-58.
28. J. Bostner, M.A. Waltersson, T. Fornander, L. Skoog, B. Nordenskjold and O. Stal, Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer, Oncogene 26 (2007), 6997-7005.
29. C.J. Ormandy, E.A. Musgrove, R. Hui, R.J. Daly and R.L. Sutherland, Cyclin D1, EMS1 and 11q13 amplification in breast cancer, Breast Cancer Research and Treatment 78 (2003), 323-335.
30. C.K. Anders, C.R. Acharya, D.S. Hsu, G. Broadwater, K. Garman, J.A. Foekens, Y. Zhang, Y. Wang, K. Marcom, J.R. Marks, S. Mukherjee, J.R. Nevins, K.L. Blackwell and A. Potti, Age-Specific Differences in Oncogenic Pathway Deregulation Seen in Human Breast Tumors, PLoS ONE 3 (2008), e1373.
31. K. Al-Kuraya, P. Schraml, J. Torhorst, C. Tapia, B. Zaharieva, H. Novotny, H. Spichtin, R. Maurer, M. Mirlacher, O. Kochli, M. Zuber, H. Dieterich, F. Mross, K. Wilber, R. Simon and G. Sauter, Prognostic relevance of gene amplifications and coamplifications in breast cancer, Cancer Research 64 (2004), 8534-8540.